Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina
- PMID: 27223650
- PMCID: PMC4909034
- DOI: 10.1590/0074-02760160006
Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina
Abstract
This study aimed to evaluate well-documented diagnostic antigens, named B13, 1F8 and JL7 recombinant proteins, as potential markers of seroconversion in treated chagasic patients. Prospective study, involving 203 patients treated with benznidazole, was conducted from endemic areas of northern Argentina. Follow-up was possible in 107 out of them and blood samples were taken for serology and PCR assays before and 2, 3, 6, 12, 24 and 36 months after treatment initiation. Reactivity against Trypanosoma cruzi lysate and recombinant antigens was measured by ELISA. The rate of decrease of antibody titers showed nonlinear kinetics with an abrupt drop within the first three months after initiation of treatment for all studied antigens, followed by a plateau displaying a low decay until the end of follow-up. At this point, anti-B13, anti-1F8 and anti-JL7 titers were relatively close to the cut-off line, while anti-T. cruzi antibodies still remained positive. At baseline, 60.8% (45/74) of analysed patients tested positive for parasite DNA by PCR and during the follow-up period in 34 out of 45 positive samples (75.5%) could not be detected T. cruzi DNA. Our results suggest that these antigens might be useful as early markers for monitoring antiparasitic treatment in chronic Chagas disease.
Figures



Similar articles
-
Levels of anti-B13 antibodies over time in a cohort of chronic infected by Trypanosoma cruzi. Its relationship with specific treatment and clinical status.Acta Trop. 2021 Jun;218:105908. doi: 10.1016/j.actatropica.2021.105908. Epub 2021 Mar 28. Acta Trop. 2021. PMID: 33789152
-
Evaluation of the ELISA-F29 test as an early marker of therapeutic efficacy in adults with chronic Chagas disease.Rev Inst Med Trop Sao Paulo. 2013;55(3):S0036-46652013000300167. doi: 10.1590/S0036-46652013000300005. Rev Inst Med Trop Sao Paulo. 2013. PMID: 23740013
-
Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.Acta Trop. 2013 Oct;128(1):130-6. doi: 10.1016/j.actatropica.2013.07.003. Epub 2013 Jul 20. Acta Trop. 2013. PMID: 23880286
-
Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).Cochrane Database Syst Rev. 2020 Dec 11;12(12):CD004102. doi: 10.1002/14651858.CD004102.pub3. Cochrane Database Syst Rev. 2020. PMID: 33305846 Free PMC article.
-
[Treatment of Trypanosoma cruzi infection in the indeterminate phase: experience and current guidelines in Argentina].Medicina (B Aires). 1999;59 Suppl 2:166-70. Medicina (B Aires). 1999. PMID: 10668259 Review. Spanish.
Cited by
-
Chagas disease in Brazil: new challenges and perspectives for old problems.Mem Inst Oswaldo Cruz. 2025 Jul 18;120:e240279. doi: 10.1590/0074-02760240279. eCollection 2025. Mem Inst Oswaldo Cruz. 2025. PMID: 40699036 Free PMC article.
-
Seroepidemiological Survey of Chronic Chagas Disease in a Rural Community in Southern Bahia, Brazil, Using Recombinant Chimeric Antigens.Pathogens. 2023 Oct 7;12(10):1222. doi: 10.3390/pathogens12101222. Pathogens. 2023. PMID: 37887738 Free PMC article.
-
A novel Trypanosoma cruzi secreted antigen as a potential biomarker of Chagas disease.Sci Rep. 2020 Nov 11;10(1):19591. doi: 10.1038/s41598-020-76508-1. Sci Rep. 2020. PMID: 33177582 Free PMC article.
-
The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease.J Clin Microbiol. 2017 Dec;55(12):3444-3453. doi: 10.1128/JCM.01317-17. Epub 2017 Oct 4. J Clin Microbiol. 2017. PMID: 28978686 Free PMC article.
-
A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients.PLoS Negl Trop Dis. 2018 Feb 9;12(2):e0006226. doi: 10.1371/journal.pntd.0006226. eCollection 2018 Feb. PLoS Negl Trop Dis. 2018. PMID: 29425201 Free PMC article.
References
-
- Affranchino JL, Ibanez CF, Luquetti AO, Rassi A, Reyes MB, Macina RA, et al. Identification of a Trypanosoma cruzi antigen that is shed during the acute phase of chagas’ disease. Mol Biochem Parasitol. 1989;34(3):221–228. - PubMed
-
- Cançado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo. 2002;44(1):29–37. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical